Outputs (795)

High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only (2024)
Journal Article
Sculthorpe, D. J., Denton, A., Fadhil, W., Rusnita, D., Ilyas, M., & Mukherjee, A. (2024). High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only. American Journal of Clinical Pathology, https://doi.org/10.1093/ajcp/aqae145

Objectives
As mismatch repair status confers differential prognosis in colorectal cancers, this study aimed to determine associations of α–smooth muscle actin (α-SMA) protein expression in mismatch repair–proficient (pMMR) and mismatch repair–defici... Read More about High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only.

Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer (2024)
Journal Article
Lashen, A. G., Toss, M. S., Rutland, C. S., Green, A. R., Mongan, N. P., & Rakha, E. (2024). Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer. Pathobiology, https://doi.org/10.1159/000540790

Introduction: Minichromosome maintenance complex component 7 (MCM7) plays an essential role in proliferation and DNA replication of cancer cells. However, the expression and prognostic significance of MCM7 in breast cancer (BC) remain to be defined.... Read More about Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer.

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study (2024)
Journal Article
Zelenetz, A. D., Jurczak, W., Ribrag, V., Linton, K., Collins, G. P., Jiménez, J. L., Bishton, M., Dholaria, B., Mengarelli, A., Phillips, T. J., Sungala, N., Musuraca, G., Sheehy, O., Van Den Neste, E., Odera, M., Miao, L., Gold, D. P., Ghalie, R. G., & Zinzani, P. L. (2024). The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study. HemaSphere, 8(8), Article e138. https://doi.org/10.1002/hem3.138

In this global phase 2 study in patients with relapsed/refractory follicular lymphoma (FL), zandelisib was administered on intermittent dosing to mitigate immune‐related adverse events and infections that have been reported with oral PI3Kδ inhibitors... Read More about The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020 (2024)
Journal Article
Liu, H., Stanworth, S. J., McPhail, S., Bishton, M., Rous, B., Bacon, A., & Coats, T. (2024). Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020. Blood Advances, 8(17), 4593-4605. https://doi.org/10.1182/bloodadvances.2024013102

We report 1- and 5-year survival following AML diagnosis and early mortality, within 30 days of systemic anti-cancer therapy (SACT) treatments, using national cancer registry data in England.

Patients aged 18-99 years diagnosed between 2013 and 2... Read More about Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020.

Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer (2024)
Journal Article
Sculthorpe, D., Denton, A., Rusnita, D., Fadhil, W., Ilyas, M., & Mukherjee, A. (2024). Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer. Pathology - Research and Practice, 260, Article 155470. https://doi.org/10.1016/j.prp.2024.155470

As pathology moves towards digitisation, biomarker profiling through automated image analysis provides potentially objective and time-efficient means of assessment. This study set out to determine how a complex membranous immunostain, E-cadherin, ass... Read More about Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer.

A novel and selective fluorescent ligand for the study of adenosine A2B receptors (2024)
Journal Article
Patera, F., Mistry, S. J., Kindon, N. D., Comeo, E., Gouding, J., Kellam, B., Kilpatrick, L. E., Franks, H., & Hill, S. J. (2024). A novel and selective fluorescent ligand for the study of adenosine A2B receptors. Pharmacology Research and Perspectives, 12(4), Article e1223. https://doi.org/10.1002/prp2.1223

Fluorescent ligands have proved to be powerful tools in the study of G protein-coupled receptors in living cells. Here we have characterised a new fluorescent ligand PSB603-BY630 that has high selectivity for the human adenosine A2B receptor (A2BR).... Read More about A novel and selective fluorescent ligand for the study of adenosine A2B receptors.

The characteristics and prognostic significance of histone H1 expression in breast cancer (2024)
Journal Article
Lashen, A. G., Almalki, N., Toss, M., Mirza, S., Malki, M. I., Rutland, C. S., Jeyapalan, J. N., Green, A. R., Mongan, N. P., Madhusudan, S., & Rakha, E. A. (2024). The characteristics and prognostic significance of histone H1 expression in breast cancer. Pathology, 56(6), 826-833. https://doi.org/10.1016/j.pathol.2024.03.012

Histone H1 (H.H1) is involved in chromatin organisation and gene regulation and is overexpressed in many malignant tumours, including breast cancer (BC). This study proposed and evaluated the prognostic role of H.H1 expression in BC.

H.H1 mRNA exp... Read More about The characteristics and prognostic significance of histone H1 expression in breast cancer.

Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy (2024)
Journal Article
Masisi, B. K., El Ansari, R., Alfarsi, L., Fakroun, A., Erkan, B., Ibrahim, A., Toss, M., Ellis, I. O., Rakha, E. A., & Green, A. R. (2024). Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy. Cancers, 16(11), Article 1949. https://doi.org/10.3390/cancers16111949

Background: Breast cancer (BC) remains heterogeneous in terms of prognosis and response to treatment. Metabolic reprogramming is a critical part of oncogenesis and a potential therapeutic target. Glutaminase (GLS), which generates glutamate from glut... Read More about Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy.

Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value (2024)
Journal Article
Alhudiri, I., Nolan, C., Ellis, I., Elzagheid, A., Green, A., & Chapman, C. (2024). Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value. Breast Cancer Research and Treatment, 206(1), 143-153. https://doi.org/10.1007/s10549-024-07293-y

Purpose
Cathepsin D is a proteolytic enzyme that is normally localized in the lysosomes and is involved in the malignant progression of breast cancer. There are conflicting results regarding Cathepsin D significance as prognostic and predictor marke... Read More about Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value.

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial (2024)
Journal Article
McIlroy, G., Lax, S., Gaskell, C., Jackson, A., Rhodes, M., Seale, T., Fox, Hopkins, L., Okosun, J., Barrington, S. F., Ringshausen, I., Ramsay, A. G., Calaminici, Linton, K., & Bishton, M. (2024). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial. BMC Cancer, 24, Article 370. https://doi.org/10.1186/s12885-024-12112-0

Background
Relapsed or refractory follicular lymphoma (rrFL) is an incurable disease associated with shorter remissions and survival after each line of standard therapy. Many promising novel, chemotherapy-free therapies are in development, but few a... Read More about Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.